Veracyte (VCYT) Stock Analysis & AI Equity Report
Veracyte (VCYT) overview
Veracyte (VCYT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 517m and operating profit of USD 57.8m; the year-end share price was 42.10 USD and market capitalisation was USD 3,341m. Veracyte is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Veracyte's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Veracyte
Veracyte is a diagnostics company that develops molecular tests to inform cancer diagnosis, prognosis and treatment decisions. Its tests cover prostate, thyroid, breast and bladder cancers, with offerings delivered through its U.S. clinical laboratories and international distribution to laboratories and hospitals. Clinicians use the test results to guide care, while the company also develops genomic and clinical evidence to support test use.
Generate the Veracyte report
Veracyte is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Veracyte and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Veracyte
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.